Researchers have solved a 100-year-old mystery, providing them a possible key to unlock a pathway for treating diseases caused by flesh-eating bacteria. Medical researchers have found a critical target on which to focus for developing a potential Group A Streptococcus vaccine or antibiotic to fight it. By manipulating this target, they hope to either reduce the severity of these infections or clear them up faster.
Scientists have made a significant discovery in efforts to develop a vaccine against Zika, dengue and Hepatitis C viruses that affect millions of people around the world.
The discovery of a mechanism by which normal brain cells regulate the expression of the NFIA gene, which is important for both normal brain development and brain tumor growth, might one day help improve therapies to treat brain tumors.
Recent outbreaks of Zika virus have revealed that the virus causes brain defects in unborn children. But researchers now report that the virus could eventually be used to target and kill cancer cells in the brain.
Medical treatment that targets human proteins rather than ever-mutating viruses may one day help HIV-positive people whose bodies have built a resistance to ‘cocktails’ currently used to keep them healthy. Now researchers have pinpointed a protein variant that can be targeted to prevent the human immunodeficiency virus from harming HIV-positive individuals.
There may no silver bullet for treating liver cancer or fatty liver disease, but knowing the right targets will help science develop the most effective treatments. Researchers have just identified a number of drug targets that can be used in the development of new efficient treatment strategies with minimum side effects.
Fresh insight into how the immune system keeps itself in check could lead to new ways of fighting chronic lung disease, report investigators.
The space under our skin might be an optimal location to treat type 1 diabetes (T1D), a group of researchers has demonstrated.
New European guidelines aim to treat brain tumors more effectively.
A phase II clinical trial shows that patients who received a hematopoietic stem cell transplant and developed a viral infection could be helped by receiving immune cells specialized in eliminating that particular virus.